ZUG, Switzerland and STOCKHOLM, April 18, 2016 /PRNewswire/ -- The who’s who in the life science industry turned out for BIO-Europe Spring® 2016 in Stockholm last week. Over 2,300 executives from 1,377 companies and 49 countries engaged in 12,452 one-to-one meetings to discuss licensing opportunities, deal potential and strategic collaborations.
In addition to the one-to-one partnering, the plenary “Environment in 2016: Reverse engineering the ecosystem” was a main feature and was moderated by Denise Scots-Knight of Mereo BioPharma Group Ltd. who was joined by Shaun Grady of AstraZeneca; Jan M. Lundberg of Eli Lilly and Company; Richard Mason of Johnson & Johnson Innovation, London; Bernd R. Seizinger of Aprea AB; and Christian Zahnd of Molecular Partners AG. Discussion focused on industry insights and what to expect from 2016 amidst less than ideal market conditions.
A highlight of the Stockholm event was the Start-up Slam: Sweden co-sponsored by Karolinska Institutet Innovations and Johnson & Johnson Innovation, which featured 17 Swedish start-up companies who engaged in a competitive session for valuable funding partners. The winner was QureTech Bio AB, a startup developing first line drugs to combat antibiotic resistance and infectious diseases.
“This was BIO-Europe Spring’s first time in Scandinavia, and we were extremely pleased with every aspect of the event and our collaboration with Stockholm Business Region and Stockholm Science City Foundation,” said Anna Chrisman, Group Managing Director, EBD Group. “We saw high levels of engagement in partnering activity and networking, indicative of a strong market and high interest in partnering and M&A.”
The next edition of BIO-Europe Spring will be held inBarcelona, Spain, March 2022, 2017.
Videos and news coverage for BIO-Europe Spring is available on partnering360:Insight and ongoing life science industry news can be found on partnering360:Blog.
Additional links and information:
Follow BIO-Europe Spring 2016 on Twitter: @EBDGroup (hashtag: #BES16).
Online Press Kit service for BIO-Europe Spring 2016 is available from Virtual Press Office/PR Newswire to enhance your public relations efforts.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America, the fastest growing partnering event in North America
- Biotech Showcase, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
- Biolatam®, facilitating partnering among global life sciences executives in Latin America’s vibrant life science hubs
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/10th-anniversary-edition-of-bio-europe-spring-2016-hosted-over-2300-life-science-industry-executives-in-stockholm-sweden-last-week-300252966.html
SOURCE EBD Group
